A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer

Sponsor
Asan Medical Center
Study ID
NCT05904457
Phase
PHASE2
Status
Unknown

Conditions

  • Advanced Solid Tumors
  • Metastatic Cancer
  • Solid Tumors

Eligibility Criteria

Sex
ALL
Age
19 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • bevacizumab — DRUG
    Patients will receive bevacizumab 10 mg/kg IV over 30-90 minutes every 2 weeks until disease progression or unacceptable toxicity.
  • erlotinib — DRUG
    Patients will receive elrotinib 150 mg orally once a day continuously until disease progression or unacceptable toxicity.

Study Details

A national, prospective, multi-center, open-label, single arm phase II trial investigating the efficacy and safety of bevacizumab plus erlotinib in patients with advanced cancers which harbors genomic alterations in Krebs cycle

Key Dates

First listed
Jun 15, 2023
Start date
Jan 2, 2023
Status verified
Jun 2023
Primary completion
Jan 31, 2025
Completion
Jan 31, 2026

Study Design

Enrollment
32 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1

Primary Outcome Measure

Objective response rate [ Time Frame: 12 months after treatment initiation (estimated average) ]

Central Contacts

Related Studies